Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NESSIE Phase II CGN in previously ICI + platinum-treated squamous NSCLC
jRCTs051200138Phase 2Completed
- Sponsor
- Nippon Kayaku Co., Ltd.
- Start
- Feb 2021
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cisplatin, gemcitabine and necitumumab in Pulmonary squamous cell carcinoma, sponsored by Nippon Kayaku Co., Ltd. Primary endpoint: Objective response rate. Started Feb 2021; status: completed.
02
Drugs
cisplatingemcitabinenecitumumab
03
Conditions
Pulmonary squamous cell carcinoma
Beyond the preview
Go deeper on jRCTs051200138.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs051200138.